Oncoinvent AS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oncoinvent AS - overview
Established
2010
Location
Oslo, -, Norway
Primary Industry
Pharmaceuticals
About
Based in Norway, Oncoinvent AS is a radiopharmaceutical company focused on developing innovative treatments for cancer through targeted alpha therapy. Their approach aims to enhance treatment efficacy while minimizing damage to healthy tissues. Oncoinvent AS specializes in the development of radiopharmaceuticals designed for cancer treatment. Founded in 2010 and headquartered in Oslo, Norway, the company has successfully raised NOK 250 million in Pre-IPO funding as of June 29, 2021, from various investors including Canica and Hadean Ventures.
The company was founded by Anders Månsson and Jan Alfheim, who have a background in the medical and pharmaceutical industries. Oncoinvent focuses on creating advanced radiopharmaceuticals, with its flagship product Radspherin® currently in clinical trials. This product aims to deliver targeted alpha therapy, which localizes treatment to tumor sites while minimizing harm to surrounding healthy tissues. Their products cater to hospitals and specialized oncology centers in Europe and North America, targeting significant unmet medical needs in cancer treatment.
In 2023, Oncoinvent reported a revenue of NOK 5,971. 50 mn, with an EBITDA of NOK -12,906,705. 10. The company's revenue model relies on partnerships with healthcare institutions for the development and commercialization of their radiopharmaceuticals, involving milestone payments during clinical trials and potential royalties post-regulatory approval.
Oncoinvent plans to utilize the NOK 250 million raised in Pre-IPO funding to advance the clinical development of Radspherin®. The company aims to expand its product offerings while targeting new markets in Europe and North America, focusing on bringing innovative cancer therapies to regions with high incidence rates. The financial backing will support efforts in scaling product development and navigating the regulatory landscape for successful commercialization.
Current Investors
Canica, Geveran Trading Co., Ltd., Must Invest
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.oncoinvent.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Oncoinvent AS - timeline of key events
Oncoinvent AS - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 70,000 | 90,239 | 215,640 | 159,840 | 67,935 | 114,059 | 72,825 | 76,015 | 299,904 | 246,770 | 195,500 | 11,083,018 | - | - | - |
| % Revenue Growth (YoY) | - | 28.9% | 139.0% | (25.9%) | (57.5%) | 67.9% | (36.2%) | 4.4% | 294.5% | (17.7%) | (20.8%) | 5569.1% | - | - | - |
| EBITDA (USD) | (363,328) | (696,282) | (794,234) | (603,806) | (975,839) | (1,236,845) | (4,775,186) | (15,387,547) | (30,751,044) | (39,436,827) | (55,420,711) | (76,055,846) | - | - | - |
| Operating Income (USD) | (363,328) | (696,282) | (794,234) | (603,806) | (975,839) | (1,236,845) | (4,930,275) | (17,231,909) | (34,738,051) | (43,871,436) | (60,251,163) | (80,841,991) | - | - | - |
| Operating Margin | (519.0%) | (771.6%) | (368.3%) | (377.8%) | (1436.4%) | (1084.4%) | (6770.0%) | (22669.1%) | (11583.1%) | (17778.3%) | (30819.0%) | (729.4%) | - | - | - |
| % EBITDA Margin | (519.0%) | (771.6%) | (368.3%) | (377.8%) | (1436.4%) | (1084.4%) | (6557.1%) | (20242.8%) | (10253.6%) | (15981.2%) | (28348.2%) | (686.2%) | - | - | - |
| NET Income (USD) | (363,379) | (694,421) | (790,956) | (599,742) | (953,770) | (1,205,842) | (4,869,333) | (15,921,571) | (33,051,924) | (42,199,383) | (59,219,767) | (80,288,555) | - | - | - |
| % Net Margin | (519.1%) | (769.5%) | (366.8%) | (375.2%) | (1403.9%) | (1057.2%) | (6686.3%) | (20945.3%) | (11020.8%) | (17100.7%) | (30291.4%) | (724.4%) | - | - | - |
Oncoinvent AS - employee data
Oncoinvent AS - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of the Board | BM | ||||||
| Chairman of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.